Content Carnivores, IR Comm

This is the IR Comm account for clients of Content Carnivores. This is a Content Carnivores media channel.

[Content Carnivores, IR Comm @ir_comm]

https://t.co/q63CVRN6IR

[Content Carnivores, IR Comm @ir_comm]

Twelve years of teamwork brings @Pacylex to the brink of Phase 2 human clinical trials — a rare feat in new drug development.https://t.co/yDDWLgxa4d

[Content Carnivores, IR Comm @ir_comm]

$GOVX working on addressing the shortage of available #MPOX vaccine. Update on the disease here. https://t.co/zxL1RTloO0

[Content Carnivores, IR Comm @ir_comm]

Crystal Research Associates has issued a 17-page Company Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ). https://t.co/QWhsGuLrsx

[Content Carnivores, IR Comm @ir_comm]

GeoVax’s gene therapy candidate Gedeptin® has been selected for poster presentation at the American Association for Cancer Research (AACR) and the American Head and Neck Society (AHNS) joint Head and Neck Cancer Conference.

[Content Carnivores, IR Comm @ir_comm]

New theater production "Pins and Needles".Vaccine hesitancy on stage. #covidnomore https://t.co/jmhZXTx9oi

[B2i Digital @b2idigital]

We want to welcome @Geovax_News to the @ROTHCapital Partners 3rd Annual Healthcare Opportunities Conference October 9th. See their profile on @B2iDigital at https://t.co/5MsVsQ9rvX

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24)

We look forward to seeing the continued results from David A. Dodd, Arban Domi, Mary Hauser, Susan Hensley, MS, RAC, Kelly McKee, Mark Newman, John Niles, Tom O'Brien, Sreenivasa Rao Oruganti, J. Marc Pipas, MD, Erica Raiden, Mark Reynolds, John W. Sharkey, Jeff Welch, Ashley Zuniga, PhD PMP and the entire GeoVax Labs, Inc. team!

Thanks to the stellar team at ROTH for organizing this conference: Sagar Sheth, Byron Roth, Isabel Mattson-Pain, Amanda McAdams, Otilia "Charo" Montano, Benjamin Bowen, James Antonopoulos, Jason Wittes, Jonathan Aschoff, Ph.D., Boobalan Pachaiyappan, Ph.D. and many others

ROTH is a relationship-driven investment bank headquartered in Newport Beach, CA. For more information on ROTH, please visit https://t.co/f7LaejqxRB.

We hope you’ll be able to attend this pivotal event shaping the future of healthcare innovation.

[Content Carnivores, IR Comm @ir_comm]

#mpox https://t.co/OE5GlflME8

[Content Carnivores, IR Comm @ir_comm]

Registration Is Now Open for Tribe Public’s Webinar Event
"Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO. https://t.co/2yDzUhGwFa #mpox #vaccine $GOVX

[Content Carnivores, IR Comm @ir_comm]

Super Micro Computer: Recent Pullback Demonstrates Normalizing AI Sentiments $SMCI https://t.co/ckTZwzkt9G

[Content Carnivores, IR Comm @ir_comm]

So they say, micro-cap stocks perform even better than small caps coming out of periods of economic stagnation...I certainly hope so! #2024 #microcaps

https://t.co/qFWSD41caU

[Content Carnivores, IR Comm @ir_comm]

@GrantCardone @elonmusk On a much smaller scale, the same thing is happening to our small digital agency clients. Zero sense, automated messages after months of trying to reach a human being for assistance!

[Grant Cardone @GrantCardone]

Dear @elonmusk,

I have been attempting to spend money with your company X. I very much appreciate your commitment & investment to this platform & have been wanting to support your efforts to protect free speech since the beginning.

Your team however keeps suggesting they want me to conform or be a certain way on the platform in order to buy ads. Suggestions like, “algorithms may deprioritize accounts who comment on controversial issues….. Toyota doesn’t want to see their ads next to controversy. “

I frankly don’t care what conversation is taking place where I decided to buy an ad. Shame on me if I didn’t my audience was there to see my products.

My companies currently spend about $50M a year with Google & Meta. I would like to spend part of that with X.

Please have someone reach out to me.

Sincerely,
Grant Cardone

[GeoVax, Inc. @Geovax_News]

Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients. #infectiousdiseases #immunooncology #COVID19 #vaccines #immunocompromised #cancer $GOVX https://t.co/MBnlylgPCg

[Content Carnivores, IR Comm @ir_comm]

Speaking at the #bioutahlifesciencesummit2023 @BioUtah

[Chelli Miller @cmiller1225]

There's More than Great Snow in Utah! https://t.co/C8dcluHFXw
#UtahLifeSciencesSummit23 #notallagenciesarealike #lifesciences #medtech #biotech #pharma #conference @BioUtah

[Content Carnivores, IR Comm @ir_comm]

Presentation from vaccine company $GOVX at #EmergingGrowthConference. https://t.co/yL77Qn3qJO

[Zack Capp @zackcapp]

Kiora - AAO Late-Breaking: Kiora’s Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa #bigdeal #clinicaldata $KPRX

https://t.co/3ZlWrbb8Dk

[Bhavdip Sanghavi @bhavdip143]

Yup

$KPRX

Biggest breakthrough in the treatment of Retinitis Pigmentosa

"This new technology offers hope to patients living with late stage inherited retinal diseases. The mechanism of action and trial data firmly support KIO-301’s continued development, potentially filling a major unmet need in the search for treatments for these patients,” said Dr. Van Gelder

[John Zidar aka/ Stock Wizard @JohnZidar]

$KPRX - Kiora Pharmaceuticals, Inc.
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

👆 Up 8.5% Pre-Market/ Current Price $0.67